Evidence map›Paper›PMID 34558848›Full record

ArticleHepatology communications2022

Predictors of Jaundice Resolution and Survival After Endoscopic Treatment of Primary Sclerosing Cholangitis.

John E Eaton, Abdul Haseeb, Christian Rupp, Leonardo H Eusebi, Kim van Munster, Robert Voitl, Douglas Thorburn, Cyriel Y Ponsioen, Felicity T Enders, Bret T Petersen and 11 more

Open access · goldAbstract read
In one paragraph

Article in Hepatology communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Primary sclerosing cholangitis.Nature reviews. Disease primers · 2025
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 4 countries.

John E EatonDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Abdul HaseebDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Christian RuppDepartment of Internal Medicine IV, University Hospital of Heidelberg, Heidelberg, Germany.
Leonardo H EusebiSheila Sherlock Liver Centre, Royal Free Hospital and the University College London Institute of Liver and Digestive Health, London, United Kingdom.
Kim van MunsterAmsterdam Universitair Medische Centra, Amsterdam, the Netherlands.
Robert VoitlDepartment of Internal Medicine IV, University Hospital of Heidelberg, Heidelberg, Germany.
Douglas ThorburnSheila Sherlock Liver Centre, Royal Free Hospital and the University College London Institute of Liver and Digestive Health, London, United Kingdom.
Cyriel Y PonsioenAmsterdam Universitair Medische Centra, Amsterdam, the Netherlands.
Felicity T EndersDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Bret T PetersenDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Barham K Abu DayyehDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Todd H BaronDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Vinay ChandrasekharaDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Christopher J GostoutDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Michael J LevyDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
John MartinDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Andrew C StormDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Ross DierkhisingDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Patrick S KamathDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Gregory J GoresDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Mark TopazianDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Mayo Clinic in Arizona · USUniversity College London · GBAmsterdam University Medical Centers · NLHeidelberg University · DEMayo Clinic · USUniversity Hospital Heidelberg · DEUniversity of Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The benefit of endoscopic retrograde cholangiopancreatography (ERCP) for the treatment of primary sclerosing cholangitis (PSC) remains controversial. To identify predictors of jaundice resolution after ERCP and whether resolution is associated with improved patient outcomes, we conducted a retrospective cohort study of 124 patients with jaundice and PSC. These patients underwent endoscopic biliary balloon dilation and/or stent placement at an American tertiary center, with validation in a separate cohort of 102 patients from European centers. Jaundice resolved after ERCP in 52% of patients. Median follow-up was 4.8 years. Independent predictors of jaundice resolution included older age (P = 0.048; odds ratio [OR], 1.03 for every 1-year increase), shorter duration of jaundice (P = 0.059; OR, 0.59 for every 1-year increase), lower Mayo Risk Score (MRS) (P = 0.025; OR, 0.58 for every 1-point increase), and extrahepatic location of the most advanced biliary stricture (P = 0.011; OR, 3.13). A logistic regression model predicted jaundice resolution with area under the receiver operator characteristic curve of 0.67 (95% confidence interval, 0.5-0.79) in the validation set. Independent predictors of death or transplant during follow-up included higher MRS at the time of ERCP (P < 0.0001; hazard ratio [HR], 2.33 for every 1-point increase), lower total serum bilirubin before ERCP (P = 0.031; HR, 0.91 for every 1 mg/dL increase), and persistence of jaundice after endoscopic therapy (P = 0.003; HR, 2.30). Conclusion: Resolution of jaundice after endoscopic treatment of biliary strictures is associated with longer transplant-free survival of patients with PSC. The likelihood of resolution is affected by demographic, hepatic, and biliary variables and can be predicted using noninvasive data. These findings may refine the use of ERCP in patients with jaundice with PSC.

Indexed as

Cholangitis, SclerosingCholestasisJaundiceCatheterizationCholangiopancreatography, Endoscopic RetrogradeHumansRetrospective Studies

Identifiers

PMID34558848
PMCPMC8948596
OpenAlexW3198073649

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.